Press Release: Pulmagen Therapeutics : Newly released market study: Pulmagen Therapeutics LLP - Pharmaceuticals & Healthcare - Deals and Alliances Profile

(PR-inside.com) Pulmagen Therapeutics LLP (Pulmagen) is a respiratory drug development company. It undertakes the development of drugs for the treatment of chronic respiratory diseases such as chronic obstructive pulmonary disease (COPD), and asthma. Pulmagen develops a wide range of respiratory products such as respiratory products such as oral CRTh2 antagonists, inhaled bronchodilators, inhaled peroxisome proliferator-activated receptor gamma agonists, and inhaled corticosteroid re-sensitizers, among others. Its pipeline product portfolio includes ADC3680, ADC9971, ADC7405, AZD2115, AZD8683, ADC3277, ADC8316 and ADC4022. The company operates in partnerships with companies such as Skyepharma, AstraZeneca, Chiesi, Dr. Reddy's and Teijin to develop its pipeline products. Pulmagen is ..